After attempting to get through the initial public offering window without success during 2021-2022, Elicio Therapeutics is taking its lymph node-directed cancer vaccine technology public through a reverse merger with troubled Angion Biomedica Corp., which began considering strategic options last summer after multiple clinical development setbacks with its renal disease candidate ANG-3777.
The US biotechs announced their plan to merge on 17 January in an all-stock transaction agreed to unanimously by both...
Welcome to Scrip
Create an account to read this article
Already a subscriber?